ワークショップ3 ドライバー遺伝子陽性肺がんに対する治療戦略

[WS3-4] TRUST-II：Updated Efficacy and Safety of Taletrectinib for ROS1+Non–Small Cell Lung Cancer

^○Yuichiro Ohe¹, Noriko Yanagitani², Shunichi Sugawara³, Hidetoshi Hayashi⁴, Yutaka Fujiwara⁵, Koichi Goto⁶, Toshiaki Takahashi⁷, Ryo Toyozawa⁸, Xianyu Zhang⁹, Shuanglian Li⁹, Rose K. Lai⁹, Nathan A. Pennell¹⁰, Maurice Perol¹¹, Lyudmila Bazhenova¹², Takashi Seto⁸ (1.National Cancer Center Hospital, Tokyo, Japan, 2.The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, 3.Sendai Kosei Hospital, Sendai, Japan, 4.Kindai University Hospital, Osaka, Japan, 5.Aichi Cancer Center Hospital, Nagoya, Japan, 6.National Cancer Center Hospital East, Kashiwa, Japan, 7.Shizuoka Cancer Center, Shizuoka, Japan, 8.National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, 9.Nuvation Bio, New York, NY, USA, 10.Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA, 11.Léon Bérard Cancer Center, Lyon, France, 12.University of California San Diego Moores Cancer Center, San Diego, CA, USA)

アンコール演題